Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.

Blood advances - 10 May 2022

Weinberg Olga K, Siddon Alexa, Madanat Yazan F, Gagan Jeffrey, Arber Daniel A, Dal Cin Paola, Narayanan Damodaran, Ouseph Madhu M, Kurzer Jason H, Hasserjian Robert P

Abstract excerpt

A subset of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) show complex karyotype (CK), and these cases include a relatively high proportion of cases of therapy-related myeloid neoplasms and TP53 mutations. We aimed to evaluate the clinicopathologic features of outcome of 299 AML and MDS patients with CK collected from multiple academic institutions. Mutations were present in 287 patients (96%),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Karyotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Neoplasms, Second Primary

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 35073573
DOI: 10.1182/bloodadvances.2021006239
PMCID: PMC9092405

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.PMID 35073573Read ↗

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.Semantic proximity Read ↗

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.Semantic proximity Read ↗

Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.Semantic proximity Read ↗

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.Semantic proximity Read ↗

Therapy-related myeloid neoplasms with single-hit TP53 mutations share the clinical, molecular, and survival characteristics of their multi-hit counterparts.Semantic proximity Read ↗

Therapy-related myeloid neoplasms.Semantic proximity Read ↗

Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience.Semantic proximity Read ↗

Complex Karyotype and TP 53 Alterations in AML and MDSSemantic proximity Read ↗

Acute Myeloid Leukemia and Myelodysplastic Syndromes with TP53 Aberrations - A Distinct Stem Cell Disorder.Semantic proximity Read ↗

Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype.Semantic proximity Read ↗

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?Semantic proximity Read ↗

TP53 in AML and MDS: The new (old) kid on the block.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.